首页> 外文期刊>Human vaccines >Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine.
【24h】

Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine.

机译:用低剂量的重组乙型肝炎疫苗对青春期前儿童接种后的抗体和免疫记忆持久性。

获取原文
获取原文并翻译 | 示例
           

摘要

Little is known about the impact of low-dose hepatitis B vaccine on the persistence of anti-HBs and immune memory in school-age children. Recombivax-HB 2.5 mug (RB) has been widely used in school-age children. RB induces high seropro-tection rates, but relatively low anti-HBs titers. The main objectives of this phase of the study were to assess anti-HBs persistence and the presence of immune memory 10 years post-vaccination of 8-10 year-old children with 3 doses of RB and the persistence of anti-HBs post-booster dose administration 5 (Group A; n=250) or 10 years (Group B; n=263) post-vaccination. No significant difference was observed between GMTs and the proportion of subjects with anti-HBs titers > =10mlU/mL 5 or lOyears post-vaccination. In both groups, a 56-fold decrease of anti-HBs GMTs was observed. One month post-booster, all but two subjects in Group A had an anti-HBs titer >=10mlU/mL A 4.9- and 11.4-fold decrease in anti-HBs GMTs were observed during the first year post-booster in Group A and B, respectively. One year post-booster, the two groups were equivalent: >98.8% of subjects had an anti-HBs >=10mlU/mL In group A, five years post-booster, 96.8% had a titer >10=mlU/mL; the GMT was 17-fold higher than the GMT 5 years post-vaccination (p<0.000l). In both groups, there was a strong positive correlation (p<0.000l) between anti-HBs titers observed post-primary vaccination and at following study time points (r=0.70-0.90). Three doses of RB administered at the age of 8-10 years induce a 10 years long-lasting immunity in virtually all vaccinees. The booster does not appear necessary on a 10 years perspective.
机译:关于低剂量乙型肝炎疫苗对学龄儿童抗-HBs持久性和免疫记忆的影响知之甚少。 Recombivax-HB 2.5马克杯(RB)已被广泛用于学龄儿童。 RB引起较高的血清保护率,但抗HBs滴度相对较低。该研究阶段的主要目标是评估3剂RB的8-10岁儿童接种疫苗后10年的抗HBs持久性和免疫记忆的存在以及加强接种后抗HBs的持久性疫苗接种后5次(A组; n = 250)或10年(B组; n = 263)剂量给药。接种后5年或10年,GMT与抗HBs滴度> = 10mlU / mL的受试者比例之间无显着差异。在两组中,均观察到抗HBs GMT降低了56倍。加强免疫后一个月,A组中除两名以外的所有受试者的抗HBs滴度均> = 10mlU / mL。在加强免疫后的第一年,A组中抗HBs GMT下降了4.9倍和11.4倍。 B分别。加强免疫后一年,两组是等效的:> 98.8%的受试者抗HBs> = 10mlU / mL在A组中,加强免疫后五年,96.8%的效价> 10 = mlU / mL;接种疫苗5年后的GMT值比GMT高17倍(p <0.000l)。在两组中,初次接种疫苗后和随后的研究时间点观察到的抗-HBs滴度之间均存在很强的正相关(p <0.000l)(r = 0.70-0.90)。几乎在所有疫苗中,三剂RB的剂量在8-10岁时均可产生10年的持久免疫力。从10年的角度来看,助推器似乎没有必要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号